2,004 results on '"Wolchok, Jedd D."'
Search Results
202. Modulation of CTLA-4 and GITR for Cancer Immunotherapy
203. IL-12-expressing highly immunogenic recombinant modified vaccinia virus Ankara reprograms tumor-infiltrating myeloid cells to overcome immune resistance
204. Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
205. A phase II study of N-acetylcysteine in cancer patients with severe COVID-19: clinical outcomes and biological correlates
206. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
207. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice
208. Introduction by the Guest Editors: The PD-1 Axis in Cancer Therapy: The Irony in a Name
209. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
210. Cancer’s Off Switch
211. Vaccines as Targeted Cancer Therapy
212. Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors
213. Nivolumab and Ipilimumab in Advanced Melanoma
214. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
215. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials
216. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
217. Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.
218. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
219. Abstract 4167: Combination of cyclophosphamide with immune checkpoint blockade inhibition elicits potent tumor control in a preclinical melanoma model
220. Abstract 250: Activating canonical p53 functions in tumor-associated macrophages improves immune checkpoint blockade efficacy
221. Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
222. Abstract 1291: APR-246 enhances tumor immunogenicity even in the absence of p53
223. Abstract 6150: Potential role of CD47 in T cell exhaustion program
224. Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.
225. Clinical characteristics and molecular features of non-small cell lung cancers (NSCLCs) following disease progression on immune checkpoint inhibitors (ICIs).
226. Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).
227. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
228. A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.
229. Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness
230. Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
231. Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions
232. Fundamental immune–oncogenicity trade-offs define driver mutation fitness
233. Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
234. Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
235. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
236. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study)
237. Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects
238. Melanoma Antigens : Vaccines and Monoclonal Antibodies
239. Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
240. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma
241. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
242. Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
243. Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors
244. Ipilimumab and whole brain radiation therapy for melanoma brain metastases
245. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
246. Correction to: Strategies for Predicting Response to Checkpoint Inhibitors
247. Anatomic position determines oncogenic specificity in melanoma
248. Reply to T. Olivier et al
249. Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism
250. CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.